AstraZeneca and Vodafone enter partnership to improve cardiovascular health
The recent announcement of a global partnership between Vodafone and the UK’s AstraZeneca is bent on assisting patients with serious cardiovascular conditions. This relationship will work with various healthcare professionals using mobile technology to increase patient communication capabilities: both mHealth and internet-based mHealth services.
Taking lead on the project, AstraZeneca’s Intelligent Pharmaceutical Group will spearhead the project’s management and development components, with Vodafone’s technology, infrastructure and expertise as the backbone behind its ideas.
Vodafone’s Director for its Machine to Machine program stated, “Bringing together the best in connectivity with the best in treatment and education will create powerful and compelling outcomes for patients. AstraZeneca is a global leader in the mHealth field and we are delighted to work with them to develop these innovative services.”